+ All Categories
Home > Documents > CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain...

CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain...

Date post: 15-Jul-2020
Category:
Upload: others
View: 1 times
Download: 0 times
Share this document with a friend
55
Transcript
Page 1: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International
Page 2: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

I

CONTENTS

Acronyms ........................................................................................................................................ II

Acknowledgments.......................................................................................................................... III

Background .................................................................................................................................... IV

Executive Summary ......................................................................................................................... 1

Reporting Rates (Table 1A) ............................................................................................................. 3

Reporting Details by Provinces and NGOs (Table 1B) ..................................................................... 4

The Summary of Overall Value Indicators (Table 2A) ..................................................................... 6

The Summary of Value Indicators by Levels (Table 2B) .................................................................. 7

The Consumed Value of HMIS Indicator Medicines for MIAR (Table 2C) .................................... 11

The Consumed Value of HMIS Indicator Medicines for HMIR (Table 2D) .................................... 12

The Consumed Value of RMNCH Medicines (Table 2E) ................................................................ 13

Summary for ABC Analysis for All Consumed Medicines (Table 3A1) .......................................... 17

Class A Items for ABC Analysis of All Consumed Medicines (Table 3A2) ..................................... 18

Summary of ABC Analysis for HMIS Indicator Medicines (Table 3B1) .......................................... 22

ABC Analysis for All HMIS Indicator Medicines (Table 3B2) ......................................................... 23

Quarterly Public Expenditures on Medicines per Patient/Client (Table 4A) ................................ 31

Quarterly Public Expenditures on Medicines per Capita (Table 4B) ............................................ 33

Average HF Days of Stock-out for Each Medicine (Table 5A) ....................................................... 35

The Summary of the Overall Volume Indicators for HMIS Indicator Medicines (Table 6) ........... 45

Page 3: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

II

Acronyms

BDN Bakhtar Development Network

BPHS Basic Package of Health Services

CAF Care of Afghan Families

CPDS Coordinated Procurement and Distribution System

DIC Data and Information Committee

EPHS Essential Package of Hospital Services

GCMU Grant Contract Management Unit

GDPA General Directorate for Pharmaceutical Affairs

HF Health facility

HMIR Hospital Monthly Inpatient Report

HMIS Health Management Information System

HN-TPO Health Net Trans-Cultural Psychosocial Organization

M&E Monitoring and Evaluation

MIAR Monthly Integrated Activity Report

MoPH Ministry of Public Health

MSH Management Sciences for Health

NGO Nongovernmental Organization

PCH Partnership Contracts for Health

PLIS Pharmaceutical Logistics Information System

PMIS Pharmaceutical management information system

RMNCH Reproductive, maternal, newborn and child health

SCA Swedish Committee for Afghanistan

SCD Supply Chain Development

SPS Strengthening Pharmaceutical Systems

USAID US Agency for International Development

Page 4: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

III

Acknowledgments

The MoPH would like to express its appreciation to the following professionals for their contribution and technical support to the PLIS and generating of PLIS quarterly reports:

Pharm. Nazir Ahmad Ahmadzad Planning Manager of Planning Dept. MoPH/GDPA

Dr. Ajmal Yadgari CPDS Technical Coordinator MoPH/GDPA

Syed Asmatullah Fatimi PLIS Consultant MoPH/GDPA

Ajmal Sediqi PLIS Consultant MoPH/GDPA

Pharm. Nanyali Gulistani Staff of Planning Dept. MoPH/GDPA

Pharm. Homa Musawi Staff of Planning Dept. MoPH/GDPA

Pharm. Sayed Hassan Staff of Planning Dept. MoPH/GDPA

Pharm. Khalil Veijah Staff of Planning Dept. MoPH/GDPA

Pharm. Zakiullah Azizi Staff of Planning Dept. MoPH/GDPA

Jamshid Sabiri HMIS Specialist MoPH

Dr. Zmary Saleh Pharmacy Manager BDN

Pharm. Hashmatullah Hayat Pharmacy Officer CAF

Pharm. Khalil-ur-Rahman Pharmacy Procurement Manager HN-TPO

Dr. Khalil Jibran Senior BPHS Officer SCA

Hafizullah Mahmoodi M&E/PMIS Advisor SPS

Dr. Najia Dehzad SCD Advisor SPS

Dr. Mohammad Osman Zaki Technical Officer SPS

Ahmad Seyar Samadi Database Developer SPS

Dr. Paul Ickx Senior Principal Technical Advisor SPS

Ms. Shiou-Chu Judy Wang Senior Technical Advisor SPS

Special thanks also go to all the participating BPHS/EPHS implementers for their cooperation and support. The PLIS quarterly reports would not be possible without the full and active participation of these implementers.

The MoPH is also grateful for the generous financial support from the US Agency for International Development (USAID).

Page 5: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

IV

Background

Afghanistan’s Ministry of Public Health (MoPH) has contracted out the implementation of Basic Package of Health Services (BPHS) and the Essential Package of Hospital Services (EPHS) services to national or international nongovernmental organizations (NGOs) with the financial support of international donors since 2005. These implementer NGOs provide pharmaceutical supplies to their catchment provinces and produced customized pharmaceutical logistics reports for their own use. However, a system to coordinate and gather the pharmaceutical supply information in the public sector has been lacking, and the MoPH did not have information regarding procurement, distribution and consumption of medicine of the BPHS/EPHS implementer NGOs. The MoPH identified this gap and included the establishment of pharmaceutical management information system (PMIS) in its Health Information System Strategic Plan (GOA, 2009).

In order to coordinate the services provided by the BPHS/EPHS implementer NGOs, the MoPH established the Coordinated Procurement and Distribution System (CPDS) in 2010 (GOA/MoPH, 2010). To address the lack of pharmaceutical supply information, a Data and Information Committee (DIC) of the CPDS was established and tasked to develop a Pharmaceutical Logistics Information System (PLIS) to gather the information about pharmaceutical procurement, distribution and consumption in the BPHS/EPHS implementers and health facilities. With the support of Strengthening Pharmaceutical Systems (SPS) program, the DIC developed a PLIS quarterly reporting form and data analysis system in a Microsoft Excel application, its user manual, macro (value1) and micro (volume2) indicators. The objectives of the PLIS are to inform the value and volume of the medicines that flow through the supply chain in the BPHS/EPHS implementers between central/provincial stores and health facilities; to analyze the consumption pattern; to redistribute the medicines that are near to expire; and to further forecast the need of the medicines and the budget.

The PLIS was initially tested with eight BPHS/EPHS implementers in September 2012. It was followed by revising the reporting form and testing with all BPHS/EPHS implementer NGOs in September 2013. After improving the system, which includes developing a Microsoft Access database, the PLIS was approved by MoPH and officially launched on January 05, 2015. Since then, all BPHS/EPHS implementer NGOs are required to submit their PLIS quarterly reports to the GDPA/MoPH.

1 “Value” refers to the direct monetary value of the products [sum of (unit price*quantity)]. It does not include other handling or administrative costs. 2 “Volume” refers to the quantities of the products in their administering units (such as tablets, capsules, vials, etc.) or packing unit (such as bottles of any liquid products, or tubes of any cream/ointment etc. with indicated volumes in the medicine list).

Page 6: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

1

Executive Summary

The PLIS presents the information in the following categories:

• Reporting rates and reporting implementers: Table 1A and 1B • Value indicators for overall transactions: Table 2A, 2B, Figures 1-3 • Value indicators for the consumption of HMIS indicator medicines and RMNCH

medicines: Table 2C (MIAR), 2D (HMIR), and 2E (RMNCH) • ABC analysis for total consumed medicines: Table 3A1 and 3A2 • ABC analysis for the consumption of HMIS indicator medicines: Table 3B1 and 3B2 • Quarterly public expenditure on medicines per patient/client and per capita at the

BPHS/EPHS level: Table 4A and 4B • Average days of stock-out of medicines among health facilities: Table 5A • Summary of volume indicators for overall transactions for HMIS indicator medicines:

Table 6

Highlights for This Reporting Quarter

In this reporting quarter, 19 BPHS/EPHS implementer NGOs were contracted by MoPH. With the cooperation of these implementers, the reporting rates were 100%, 92%, and 89% for central, provincial stores, and health facilities (HFs), respectively.

The summary of the values of medicines are as follows.

Overall value indicators: • Total value of the available medicines at the beginning of quarter was

US$7,977,584.79 • Total value of medicines purchased and received through donation during the

quarter was US$3,135,945.36 • Total value of consumed medicine for the reporting quarter was US$3,564,281.03.

(See ABC analysis below). • Total reported wastage of medicine was US$226,766.71. • Total value of reported ending stock was US$8,466,522.71.

ABC analysis3 for the total consumed value (US$3,564,281):

3 ABC analysis: A method by which medicines are classified as Pareto category A, B, or C according to the monetary value of their usage (unit cost multiplied by consumption volume). The class 'A' items typically account for a large proportion of the overall value with a small percentage of number of items. In the business management, they are the priority items to be managed or controlled.

Page 7: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

2

• Only 10.38% (52 items) of the medicines accounted for 80% (US$2,832,629) of the

total consumed value. These are classified as Class A items and are the priority medicines to be managed and monitored closely.

• 12.77% (64 items) of the medicines accounted for 15% (US$551,841) of the total consumed value: Class B items.

• 76.85% (385 items) of the medicines accounted for only 5% (US$179,811) of the total consumed value: Class C items.

• Amoxicillin 500mg cap accounted for the highest consumed value (US$346,774.07), followed by co-trimoxazole 480mg tab (US$187,538.67) and amoxicillin 250mg cap (US$112,314.91).

HMIS indicator medicines: • There were 100 items of medicines in the MIAR and 40 items in HMIR reported this

quarter. • ABC analysis: only 18.80% (25 items) of the medicines accounted for 80%

(US$2,260,828) of the total HMIS medicines’ cost (US$2,827,338). • The top 3 consumed HMIS indicator medicines based on their consumption

quantities are: 1. Paracetamol 500mg tab: 20,603,556 tabs (US$105,581.38) 2. Co-trimoxazaole 480mg tab: 15,309,583 tabs (US$187,538.67) 3. Ferrous sulphate 60mg+folic acid 0.4mg tab: 10,918,658 tabs (US$68,939.13)

Reproductive, maternal, newborn and child health (RMNCH) indicator medicines:

• There were 94 RMNCH medicines reported this quarter. • The total value of consumed RMNCH medicines was US$2,156,556.97. Since some of

these medicines are widely used for other health conditions, this value is based on the grand total consumption for all treatments. It is not specific for the use in RMNCH.

Quarterly public expenditure on medicines at the BPHS/EPHS level:

• In this quarter, the public expenditure on medicines per patient/client was between US$0.11 and US$0.77 in the provinces, with the overall average of US$0.32.

• The public expenditure on medicines per capita at the BPHS/EPHS level was between US$0.05 and US$0.47 in the provinces, with the overall average of US$0.19.

Page 8: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 1A. Reporting Rates

3Quarter , 1393 (Mizan - Qaws)

Levels Central Provincial HF

This table shows the reporting rates for each level. The PLIS reports are submitted based on the provinces with which the BPHS/EPHS implementers are working. Only three implementers have central warehouses, so the number of expected reports is four (100% reports are received). The number of expected reports from the provincial level is 37, of which 34 reports are received (92%). Also this table indicates that the number of expected combined reports from health facility level is 44, of which 39 reports are received (89%).

Number of Reports Expected 3 37 44

Number of Reports Submitted 3 34 39

Reporting Rate 100% 92% 89%

Combined HF report: The report in the HF level is a combination of reports from all health facilities in that province under the management of the contracted implementer.

3

Page 9: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 1B. Reporting Details by Provinces and NGOs

3Quarter , 1393 (Mizan - Qaws)

This table shows the reporting details of each NGO with the details of their reporting level and the provinces with which they are working.

HFsProvincialCentralProvinciesNGOs Status

YesYesN/ABadakhshanCAF C

YesN/AN/ABadakhshanAKHS C

YesYesN/ABadghisMOVE C

YesYesN/ABaghlanAKHS C

YesYesN/ABaghlanBDN C

YesYesN/ABalkhBDN C

YesYesN/ABamyanAKHS C

YesYesN/ABamyanAADA C

YesYesNoDykundiPU-AMI NC

NoYesN/ADykundiCAF NC

YesYesN/AFarahCHA C

YesN/AN/AFarahMRCA C

YesYesN/AFaryabSAF C

YesYesN/AGhazniAADA C

YesYesN/AGhazniSDO C

YesN/AN/AGhazniBDN C

YesYesN/AGhorACTD C

YesYesN/AHelmandACTD C

YesYesN/AHiratBDN C

YesYesN/AJawzjanSAF C

YesN/AN/AKabulBRAC C

YesYesN/AKandaharAHDS C

NoYesN/AKapisaSM NC

YesYesN/AKhostHNTPO C

YesYesYesKunarPU-AMI C

YesYesN/AKunduzSCI C

YesN/AN/ALaghmanSCA C

YesN/AYesLogarMRCA C

YesYesN/ALogarCAF C

YesYesN/ANangarharAADA C

C= Completed (All the required reports were submitted), NC= Not Completed (Not all the required reports were submitted), NA= Not Applicable (Don’t have service at this level)

4

Page 10: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

HFsProvincialCentralProvinciesNGOs Status

YesYesN/ANangarharHNTPO C

YesYesN/ANimrozSAF C

YesYesN/ANooristanIMC C

YesYesN/APaktikaIMC C

YesYesN/APaktyaHNTPO C

YesYesN/ASamanganAADA C

YesYesN/ASar-e-PulBDN C

YesYesN/ATakharCAF C

YesYesN/AUrozganAHDS C

YesN/AN/AWardakSCA C

YesYesN/AZabulHADAAF C

C= Completed (All the required reports were submitted), NC= Not Completed (Not all the required reports were submitted), NA= Not Applicable (Don’t have service at this level)

5

Page 11: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 2A. The Summary of Overall Value Indicators

3Quarter , 1393 (Mizan - Qaws)

Beginning Stock

Total Value of Purchased and Donation during the Quarter

Total Value of Received from Central/Provincial levels during the Quarter

Total Consumed

Reported Wastage

Reported Ending Stock

Indicators

This table summarizes the overall value of the reported medicines flowing between central, provincial and health facilities. There was US$7,977,584.79 of the medicines at the beginning of the quarter, with the addition of purchases and donations during the quarter worth US$3,135,945.36. The grand total consumed value for this quarter was US$3,564,281.03, this table also shows that the total wastage was US$226,766.71, and total remaining medicines’ value at the end of quarter was US$8,466,522.71.

Value in US$

7,977,584.79

3,135,945.36

6,252,054.60

3,564,281.03

226,766.71

8,466,522.71

Beginning Stock

The stock on hand at the beginning of the quarter in all the central and provincial stores and HFs (same as the ending stock reported in the previous quarter)

Total Value of Received from Central/Provincial

Reflect the sum-up value in both provincial and health facility levels. It may include the vlaue that is received at the provincial level, and some of them distributed to health facility level, which may have double count in the "Grand Total" value.

Total Value of Purchased and Donation during the quarter

Reflect the total Medicine Purchased in Central and Provincial levels plus total Donation received in all levels during the quarter

Reported wastage

The total wastage due to expiration or damage reported by all central and provincial stores and HFs

Reported Ending stock

The stock on hand reported by all the central and all central and provincial stores and HFs 6

Page 12: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 2B. The Summary of Value Indicators by Levels3Quarter , 1393 (Mizan - Qaws)

Central Provincial HFs Grand Total

Total Value of Beginning Stock

Total Value of Purchased and Donation during the Quarter

Total Value of Recived Medicines from Central/Provincial levels

Total value of the medicines distributed

Total value of the medicines donated out

Total value of the medicines consumed

Total value of wastage

Reported total value remained at the end of the quarter

Value in US$

This table indicates the breakdown of the information shown in Table 2A at each level (central, provincial and health facilities).

7,977,584.8611,040.75 3,454,904.51 4,511,639.60

3,135,945.09797,017.42 2,327,364.02 11,563.65

6,252,054.520.00 2,200,937.86 4,051,116.66

4,700,946.82696,417.32 4,004,529.50 0.00

49,548.420.00 49,548.42 0.00

3,564,281.160.00 0.00 3,564,281.16

226,766.731.04 207,163.07 19,602.62

8,466,522.57112,029.38 3,254,164.58 5,100,328.61

Total Value of Recived Medicines from Central/Provincial levels:

Reflect the sum-up value in both provincial and health facility levels. It may include the vlaue that is received at the provincial level, and some of them distributed to health facility level, which may have double count in the "Grand Total" value.

Total Value of Purchased and Donation during the quarter

Reflect the total Medicine Purchased in Central and Provincial levels plus total Donation received in all levels during the quarter

7

Page 13: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

3Quarter , 1393 (Mizan - Qaws)

Figure 1

Figure 1: Total Value and Sources of Received Medicines at the Central Level (Value in US$)

0%

100%

0%

Direct Donation

National Purchase

From Donors

This figure displays the total value and sources of medicine at the central level. It shows that almost all the medicines at the central stores came from national purchase (US$0.79 million, 100%); the value from direct donation was very minimal.

International Purchase Direct Donation National Purchase From Donors Total

0.00 0.00 797,017.41 0.00 797,017.41

8

Page 14: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

3Quarter , 1393 (Mizan - Qaws)

Figure 2: Total Value and Sources of Received Medicines at the Provincial Level (Value in US$)

5%

19%

26%

2%

48%

International Purchase

National Purchase

From Donors

Direct Donation

Received from Central

This figure shows the total value and sources of medicine at the provincial level. It indicates that the medicines were received from five sources: direct donation, international purchase, local purchase, from donors via international purchase, and from central stores. Most of the medicines were received from central stores (US$2,200,937.94: 48%), followed by donors’ international purchases (US$ 1,176,629.74; 26%) (for PCH NGOs), and only (US$205,136.09, 5%) was purchased from international market.

International Purchase National Purchase From Donors Direct Donation Received Central Total

205,136.09 861,233.58 1,176,629.74 84,364.89 2,200,937.94 4,528,302.24

9

Page 15: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

3Quarter , 1393 (Mizan - Qaws)

Figure 3: Total value of Medicines available and consumed at the HFs level (Value in US$)

0

1000000

2000000

3000000

4000000

5000000

6000000

Value at the Beginning Value Received Donation Value Consumed Value at the end

This figure indicates the total value of medicine available and consumed at the HF level. Total value of medicine at the beginning of the quarter in all HFs was US$ 4,511,639.60 and total value of medicine received from central or provincial levels was US$ 4,051,116.66; the value of the received donation was US$ 11,563.65. The total consumption of medicines in all HFs was US$ 3,564,281.16, the value of the medicines remaining at the end of the quarter was US$ 5,100,328.61.

Value at the Beginning Value Received Donation Value Consumed Value at the end

4,511,639.60 4,051,116.66 11,563.65 3,564,281.16 5,100,328.61

10

Page 16: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 2C. The Consumed Value of HMIS Indicator Medicines for MIAR

3Quarter , 1393 (Mizan - Qaws)

The HMIS indicator medicines include those for priority health conditions such as RMNCH, infectious diseases, tuberculosis and malaria, cardiovascular diseases, psychotropic disorders, pain and fever, electrolyte or nutritional supplements, etc. This table shows the consumed value of each category and grand total of the MIAR medicines.

M# MIAR Indicator Medicines No. of Items Consumed Value in US$

M1 Acetyl Salicylic Acid/ Paracetamol 9 244,165.17

M2 Mebandazole 2 24,368.39

M3 Amoxicilin/Ampicillin 7 658,684.75

M4 INH 2 512.84

M5 Rifampicin 6 11,737.92

M6 Amp. Diazepam 1 2,148.90

M7 Inj. Lidocaine 6 5,275.39

M8 Metronidazole 8 253,826.25

M9 Co-trimoxazole 4 255,161.89

M10 Anti-hypertensives 20 53,714.61

M11 Oral contraceptive 6 77,104.59

M12 Injectable contraceptive 1 81,137.08

M13 Condoms 1 52,764.97

M14 ORS 2 131,900.03

M15 Zinc tablets 2 34,750.24

M16 Vitamin A 5 42,198.32

M17 Ferrous Sulfate + folic acid 3 116,103.42

M18 Oxytocin 1 17,328.18

M19 Chloroquine 5 14,349.39

M20 Artesunate + SP 5 11,379.49

M21 Amitriptiline/ Fluoxetine 4 25,619.82

Grand Total 100 2,114,231.62

11

Page 17: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 2D. The Consumed Value of HMIS Indicator Medicines for HMIR

3Quarter , 1393 (Mizan - Qaws)

This table shows the consumed value of each category and grand total of the HMIR medicines.

H# HMIR Indicator Medicines No. of Items Consumed Value in US$

H1 ACT 5 11,379.49

H2 Atropine inj 2 630.31

H3 Benzyl Penicilline inj 2 1,841.72

H4 Digoxin 2 217.37

H5 Ergometrine inj 4 6,536.45

H6 Furosemide inj 1 1,131.15

H7 Gentamicin inj 3 19,281.23

H8 Iodine povidone 1 16,954.56

H9 Ketamin inj 1 9,226.73

H10 Lidocaine 5% spinal inj 1 572.86

H11 Magnesium Sulphate 2 2,973.52

H12 Morphine inj 1 6,200.39

H13 Naloxone inj 1 1,259.40

H14 Hydralazine inj 1 4,618.44

H15 Pethidine inj 2 0.00

H16 Phenobarbital inj 3 358.60

H17 Quinine inj 1 889.28

H18 Ranitidine inj 1 681.30

H19 Ringer lactate IV 2 104,731.07

H20 Salbutamol inj 2 2,206.24

H21 Sodium chloride IV 2 44,792.23

Grand Total 40 236,482.34

12

Page 18: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 2E. The Consumed Value of RMNCH Medicines

3Quarter , 1393 (Mizan - Qaws)

This table shows the consumption value of RMNCH indicator medicines. In total, 94 RMNCH medicines were reported. The total value of consumed RMNCH medicines was US$ 2,156,556.97.

RMNCH Medicines Consumed Value in US$

Acetylsalicylic acid (Aspirin) 100mg tab 1,769.87

Amoxicillin 125mg + Clavulanic acid 31.25mg/5ml, in 60ml bottle, Susp 558.84

Amoxicillin 125mg/5ml, in 60ml bottle, susp 25,640.00

Amoxicillin 250mg Cap 112,314.91

Amoxicillin 250mg/5ml, in 60ml bottle, Susp 96,820.60

Amoxicillin 500mg Cap 346,774.11

Amoxicillin 500mg+Clavulanic acid 125mg (Co-amoxiclav) Tab 34.27

Ampicillin 1g vial 45,741.93

Ampicillin 500mg Tab 1,589.77

Ampicillin 500mg vial 29,803.43

Calcium 250mg Tab 68.10

Calcium Gluconate 10% 10ml Amp 578.47

Chloroquine 100mg Tab 4.48

Chloroquine 150mg Tab 7,582.06

Chloroquine 50mg/5ml 60ml Syr 6,716.12

Condom 52,764.97

Dexamethasone 4mg /ml 1ml Amp 189.50

Ergometrine 0.2mg Tab 3,439.88

Ergometrine 0.2mg/ml, 1ml Amp 1,986.95

Erythromycin (Base) 200mg/5ml, in 60ml, susp 48,213.14

Erythromycin (Ethyl Succinate) 100mg/ml 100ml Susp 5,566.21

Erythromycin Stearate 250mg Tab 9,276.72

Erythromycin Stearate 500mg Tab 17,806.42

Ethinylestradiol 0.035mg+Norethisterone 1mg Cycle 995.96

Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg Cycle 27,721.77

-Essential Interventions, Commodities and Guideline for Reproductive, Maternal, Newborn and Child Health WHO.

Note: The consumption of these medicines is not only for RMNCH, but also for other health conditions. The consumed values indicate the overall usage of these medicines in the reporting quarter.

The RMNCH Medicine List has been taken from below references:

13

Page 19: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

RMNCH Medicines Consumed Value in US$

Ethinylestradiol 0.03mg+Norgestrel 0.3mg Cycle 18,473.47

Ethinylestradiol 0.05mg+Levonorgestrel 0.25mg Cycle 0.00

Ferrous sulfate 125mg/5ml, in 120ml , oral liquid 1,135.74

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.25mg Tab 45,280.53

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.5mg Tab 1,883.75

Ferrous Sulfate 25mg/ml 120ml Drop 23,654.98

Ferrous Sulfate 60mg Tab 3,759.85

Ferrous Sulphate 200mg Tab 2,352.58

Ferrous Sulphate 60mg+Folic Acid 0.4mg Tab 68,939.14

Folic Acid 1mg Tab 1,565.06

Folic Acid 5mg Tab 7,686.65

Gentamicin 10mg/ml, 2ml Amp 2,587.99

Gentamicin 20mg/ml, 2ml Amp 5,254.22

Gentamicin 40mg/ml, 2ml Amp 11,439.02

Hydralazine 20mg/ml, in 2ml , Amp 4,618.44

Hydralazine 25mg Tab 0.00

Hydralazine 50mg Tab 0.00

Hydroxocobalamine (Vit B12) 1mg/ml, in 1ml Amp 0.00

Intrauterine device (IUD) with copper 1pce , vaginal intra uterine device 377.40

Magnesium Sulfate 500mg/ml (50%) 10ml Amp 2,808.91

Magnesium Sulfate 500mg/ml (50%) 20ml Amp 164.61

Medroxyprogesterone acetate Depot 150mg/ml, in 1ml vial 81,137.08

Methyldopa 250mg Tab 30,736.77

Methylergometrine 0.125mg Tab 687.70

Methylergometrine 0.2mg Tab 26.96

Methylergometrine 0.2mg/ml, 1ml Amp 421.92

Metronidazole 120mg/5ml, in 100ml bottle, Susp 4,603.88

Metronidazole 200mg Tab 66,587.13

Metronidazole 200mg/5ml, in 100ml bottle, Susp 56,806.06

-Essential Interventions, Commodities and Guideline for Reproductive, Maternal, Newborn and Child Health WHO.

Note: The consumption of these medicines is not only for RMNCH, but also for other health conditions. The consumed values indicate the overall usage of these medicines in the reporting quarter.

The RMNCH Medicine List has been taken from below references:

14

Page 20: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

RMNCH Medicines Consumed Value in US$

Metronidazole 250mg Tab 0.00

Metronidazole 400mg Tab 34,906.05

Metronidazole 500mg Tab 0.00

Metronidazole 5mg/ml, in 100ml bottle, infusion Sol 89,746.74

Misoprostol 200mcg Tab 555.95

Nifedipine 10mg Tab/Cap 5,534.14

Nifedipine 20mg Tab/Cap 366.47

Norethindrone 0.35mg (Progestin-Only Pills or Mini-Pills) 0.00

Norgestrel 0.03mg Cycle 28,982.31

Norgestrel 0.075mg Cycle 931.08

Oral rehydration salts (ORS , Resomal and low osmolar) 20.5g/Lit 65,944.12

Oral rehydration salts (ORS , Resomal and low osmolar) 27.9g/Lit 65,955.91

Oxytocine 10IU/ml in 1ml Amp 17,328.18

Paracetamol (Acetaminophen) 225mg/3ml, Amp (75mg/ml) 0.00

Paracetamol 100mg Tab 25,155.17

Paracetamol 100mg/ml, 15ml Drop 85.54

Paracetamol 120mg/5ml, 60ml Syr 76,690.92

Paracetamol 325mg Tab 157.87

Paracetamol 500mg Tab 105,581.41

Penicillin Benzyl (Peni G crystal) 1MU Vial 0.00

Penicillin Benzyl (Peni G crystal) 5MU Vial 1,841.72

Penicillin Benzyl Benzathine 1.2MU Vial 3,450.29

Penicillin Benzyl Benzathine 2.4MU Vial 3,428.47

Penicillin Benzyl Procaine 1MU Vial 0.00

Penicillin Benzyl Procaine 2MU Vial 1,840.53

Penicillin Benzyl Procaine 3MU Vial 6,938.73

Penicillin Benzyl Procaine 4MU Vial 1,998.87

Penicillin Benzyl Procaine 800,000U Vial 77.76

Retinol (Vit A) 100,000 IU Amp 154.90

-Essential Interventions, Commodities and Guideline for Reproductive, Maternal, Newborn and Child Health WHO.

Note: The consumption of these medicines is not only for RMNCH, but also for other health conditions. The consumed values indicate the overall usage of these medicines in the reporting quarter.

The RMNCH Medicine List has been taken from below references:

15

Page 21: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

RMNCH Medicines Consumed Value in US$

Retinol (Vit A) 100,000 IU Tab 4,957.00

Retinol (Vit A) 200,000 IU Cap 35,863.35

Retinol (Vit A) 25,000IU Cap 0.00

Retinol (Vit A) 50,000IU Cap 1,223.06

Sulfamethoxazole 100mg+Trimethoprim 20mg Tab (Co-trimoxazole) 35,520.21

Sulfamethoxazole 200mg+Trimethoprim 40mg/5ml 50ml Susp (Co-trimoxa 30,045.50

Sulfamethoxazole 400mg+Trimethoprim 80mg 50ml Susp (Co-trimoxazole) 2,057.51

Sulfamethoxazole 400mg+Trimethoprim 80mg Tab (Co-trimoxazole) 187,538.66

Zinc Sulfate 10mg Tab 0.00

Zinc Sulfate 10mg/5ml, 100ml Syr 0.00

Zinc Sulfate 20mg Tab 34,750.24

Grand Total 2,156,556.97

-Essential Interventions, Commodities and Guideline for Reproductive, Maternal, Newborn and Child Health WHO.

Note: The consumption of these medicines is not only for RMNCH, but also for other health conditions. The consumed values indicate the overall usage of these medicines in the reporting quarter.

The RMNCH Medicine List has been taken from below references:

16

Page 22: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

80

17

Page 23: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 3A2. Class A Items for ABC Analysis of All Consumed Medicines3Quarter , 1393 (Mizan - Qaws)

This table shows the medicines that cost most (class A items) from ABC analysis by the order of their consumed value (The unit prices are rounded to two decimals). It is to highlight the small portion of the medicines which accounted for majority of the cost. They are the priority medicines that need to be managed and monitored closely. For example, amoxicillin 500mg cap alone accounted for 9.73% (US$346,774.07) of the total consumed value. It is followed by co-trimoxazole 480mg tablets for 5.26% (US$187,538.67), and amoxicillin 250mg cap for 3.15% (US$112,314.91) of the total cost. These three medicines were ranked as the top three consumed medicines of the overall consumption in value.

Medicines HMIS Code Total Consumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Amoxicillin 500mg Cap 346,774.07 8,661,255 0.04 9.73 9.73 AM3

Sulfamethoxazole 400mg+Trimethoprim 80mg Tab (Co-trimoxazole)

187,538.67 15,309,583 0.01 5.26 14.99 AM9

Amoxicillin 250mg Cap 112,314.91 6,261,244 0.02 3.15 18.14 AM3

Paracetamol 500mg Tab 105,581.38 20,603,556 0.01 2.96 21.10 AM1

Amoxicillin 250mg/5ml, in 60ml bottle, Susp

96,820.64 205,260 0.46 2.72 23.82 AM3

Multivitamin Tab 96,772.10 27,253,211 0.00 2.72 26.54 A

Metronidazole 5mg/ml, in 100ml bottle, infusion Sol

89,746.73 209,080 0.42 2.52 29.05 AM8

Ringer lactate 1000ml IV infusion 85,827.10 132,770 0.66 2.41 31.46 AH19

Medroxyprogesterone acetate Depot 150mg/ml, in 1ml vial

81,137.05 160,940 0.48 2.28 33.74 AM12

Paracetamol 120mg/5ml, 60ml Syr 76,690.95 277,091 0.29 2.15 35.89 AM1

Penicillin V(Phenoxy methyl Penicillin) 250mg/5ml, in 100ml bottle, Susp

76,233.06 89,192 0.72 2.14 38.03 A

Ferrous Sulphate 60mg+Folic Acid 0.4mg Tab

68,939.13 10,918,658 0.01 1.93 39.96 AM17

Metronidazole 200mg Tab 66,587.15 6,059,796 0.01 1.87 41.83 AM8

Oral rehydration salts (ORS , Resomal and low osmolar) 27.9g/Lit

65,955.92 949,770 0.06 1.85 43.68 AM14

18

Page 24: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Consumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Oral rehydration salts (ORS , Resomal and low osmolar) 20.5g/Lit

65,944.13 1,181,593 0.06 1.85 45.53 AM14

Metronidazole 200mg/5ml, in 100ml bottle, Susp

56,806.05 173,495 0.31 1.59 47.13 AM8

Penicillin V Potassium 500mg Tab 52,792.45 1,136,561 0.04 1.48 48.61 A

Condom 52,764.97 2,302,432 0.02 1.48 50.09 AM13

Erythromycin (Base) 200mg/5ml, in 60ml, susp

48,213.15 73,342 0.62 1.35 51.44 A

Ampicillin 1g vial 45,741.89 233,786 0.19 1.28 52.72 AM3

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.25mg Tab

45,280.53 11,109,589 0.01 1.27 53.99 AM17

Tetracycline Eye 1% Oint 39,806.07 311,034 0.13 1.12 55.11 A

Sodium Chloride 0.9% 1000ml IV infusion (Normal Saline)

39,476.10 65,356 0.60 1.11 56.22 AH21

Silver Sulfadiazine 1% Oint 38,756.08 56,018 0.70 1.09 57.30 A

Retinol (Vit A) 200,000 IU Cap 35,863.36 1,270,330 0.03 1.01 58.31 AM16

Sulfamethoxazole 100mg+Trimethoprim 20mg Tab (Co-trimoxazole)

35,520.19 7,441,701 0.01 1.00 59.31 AM9

Metronidazole 400mg Tab 34,906.05 2,569,748 0.01 0.98 60.29 AM8

Zinc Sulfate 20mg Tab 34,750.22 2,245,162 0.02 0.97 61.26 AM15

Acetylsalicylic acid (Aspirin) 500mg tab 33,142.41 3,998,407 0.01 0.93 62.19 AM1

Chloramphenicol 125mg/5ml 100ml Bottle Susp

32,922.11 65,669 0.44 0.92 63.12 A

Aluminium hydroxide 500mg tab 32,384.68 3,698,777 0.01 0.91 64.02 A

Methyldopa 250mg Tab 30,736.77 1,211,225 0.03 0.86 64.89 AM10

Sulfamethoxazole 200mg+Trimethoprim 40mg/5ml 50ml Susp (Co-trimoxazole)

30,045.49 124,876 0.24 0.84 65.73 AM9

19

Page 25: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Consumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Ampicillin 500mg vial 29,803.43 219,115 0.13 0.84 66.57 AM3

Ceftriaxone 1g Vial 29,002.23 41,440 0.46 0.81 67.38 A

Norgestrel 0.03mg Cycle 28,982.31 103,099 0.27 0.81 68.19 AM11

Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg Cycle

27,721.77 222,513 0.11 0.78 68.97 AM11

Penicillin V Potassium 250mg Tab 27,599.50 1,136,807 0.03 0.77 69.74 A

Chloramphenicol 250mg Cap 26,590.03 1,459,475 0.02 0.75 70.49 A

Ciprofloxacin 250mg Tab 26,411.36 700,812 0.04 0.74 71.23 A

Ibuprofen 400 mg Tab 25,771.41 2,298,209 0.02 0.72 71.95 A

Amoxicillin 125mg/5ml, in 60ml bottle, susp 25,640.01 68,566 0.38 0.72 72.67 AM3

Cetrimide 15%+Chlorhexidine gluconate 1.5% topical Sol

25,501.56 11,144 2.07 0.72 73.39 A

Glucose 5% 500ml IV infusion 25,401.93 50,998 0.43 0.71 74.10 A

Paracetamol 100mg Tab 25,155.15 7,850,113 0.00 0.71 74.81 AM1

Ibuprofen 200mg Tab 24,765.53 4,683,269 0.01 0.69 75.50 A

Aluminium hydroxide 200mg+Magnesium hydroxide 200mg tab

24,462.23 3,252,945 0.01 0.69 76.19 A

Mebendazole 100mg Tab 24,368.37 2,361,043 0.01 0.68 76.87 AM2

Doxycycline 100mg Cap 23,840.77 1,693,652 0.01 0.67 77.54 A

Ferrous Sulfate 25mg/ml 120ml Drop 23,654.97 60,750 0.32 0.66 78.21 A

Ceftriaxone 500mg Vial 23,376.53 55,903 0.39 0.66 78.86 A

Methylrosaniline (Gentian Violet) 25g Powder

21,808.43 21,287 1.04 0.61 79.47 A

20

Page 26: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Class % Of Consumed Value in US$

Number of Medicines Consumed Value in US$

% Of Medicines

Table 3B1. Summary of ABC Analysis for HMIS Indicator Medicines

3Quarter , 1393 (Mizan - Qaws)

This table indicates the summary of ABC analysis for HMIS indicator medicines. It shows that, out of 133 of the total HMIS indicator medicines, only 18.80% (25 items) of them accounted for 80% (US$2,260,828) of the total consumed value (Class A items), 15.04% (20 items) accounted for 15% (US$421,064) of the total consumed value (Class B items), and 66.17% (88 items) accounted for only 5% (US$145,446) of the total consumed value (Class C items). This information indicates that, among HMIS medicines, these 25 class A items should be closely monitored and managed as they cost most. The next table (Table 3B2) provides details of the ABC analysis by the order of the medicines consumed values.

A 80 25 2,260,82818.80

B 15 20 421,06415.04

C 5 88 145,44666.17

Total 100 133 2,827,338100.00

21

Page 27: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 3B2. ABC Analysis for All HMIS Indicator Medicines

3Quarter , 1393 (Mizan - Qaws)

This table shows the ABC analysis for all HMIS indicator medicines with details by the order of their consumed value and ABC classes. The HMIS code represents the categories of the medicines (M for MIAR, H for HMIR). (The unit prices are rounded to two decimals). The data indicate that amoxicillin 500mg cap alone accounted for 12.27% (US$346,774.07) of the total HMIS medicines’ consumed value. It is followed by ringer lactate 1000ml IV which accounted for 9.89% (US$279,535.50) and co-trimoxazole 480mg tablets for 6.63% (US$187,538.67) of the total HMIS medicines’ consumed value. These three medicines were ranked as top three consumed HMIS indicator medicines in value.

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Amoxicillin 500mg Cap 346,774.07 8,661,255 0.04 12.27 12.27 AM3

Ringer lactate 1000ml IV infusion 279,535.50 428,624 0.67 9.89 22.15 AH19

Sulfamethoxazole 400mg+Trimethoprim 80mg Tab (Co-trimoxazole)

187,538.67 15,309,583 0.01 6.63 28.78 AM9

Sodium Chloride 0.9% 1000ml IV infusion (Normal Saline)

126,086.17 207,784 0.62 4.46 33.24 AH21

Amoxicillin 250mg Cap 112,314.91 6,261,244 0.02 3.97 37.22 AM3

Paracetamol 500mg Tab 105,581.38 20,603,556 0.01 3.73 40.95 AM1

Amoxicillin 250mg/5ml, in 60ml bottle, Susp

96,820.64 205,260 0.46 3.42 44.38 AM3

Metronidazole 5mg/ml, in 100ml bottle, infusion Sol

89,746.73 209,080 0.42 3.17 47.55 AM8

Medroxyprogesterone acetate Depot 150mg/ml, in 1ml vial

81,137.05 160,940 0.48 2.87 50.42 AM12

Paracetamol 120mg/5ml, 60ml Syr 76,690.95 277,091 0.29 2.71 53.13 AM1

Ferrous Sulphate 60mg+Folic Acid 0.4mg Tab

68,939.13 10,918,658 0.01 2.44 55.57 AM17

Metronidazole 200mg Tab 66,587.15 6,059,796 0.01 2.36 57.93 AM8

Oral rehydration salts (ORS , Resomal and low osmolar) 27.9g/Lit

65,955.92 949,770 0.06 2.33 60.26 AM14

22

Page 28: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Oral rehydration salts (ORS , Resomal and low osmolar) 20.5g/Lit

65,944.13 1,181,593 0.06 2.33 62.59 AM14

Metronidazole 200mg/5ml, in 100ml bottle, Susp

56,806.05 173,495 0.31 2.01 64.60 AM8

Ringer lactate 500ml IV infusion 56,481.57 92,063 0.50 2.00 66.60 AH19

Povidone-Iodine 10% Topical Sol 55,747.15 33,170 1.62 1.97 68.57 AH8

Condom 52,764.97 2,302,432 0.02 1.87 70.44 AM13

Ampicillin 1g vial 45,741.89 233,786 0.19 1.62 72.05 AM3

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.25mg Tab

45,280.53 11,109,589 0.01 1.60 73.65 AM17

Gentamicin 40mg/ml, 2ml Amp 37,313.22 359,692 0.12 1.32 74.97 AH7

Retinol (Vit A) 200,000 IU Cap 35,863.36 1,270,330 0.03 1.27 76.24 AM16

Sulfamethoxazole 100mg+Trimethoprim 20mg Tab (Co-trimoxazole)

35,520.19 7,441,701 0.01 1.26 77.50 AM9

Metronidazole 400mg Tab 34,906.05 2,569,748 0.01 1.23 78.73 AM8

Zinc Sulfate 20mg Tab 34,750.22 2,245,162 0.02 1.23 79.96 AM15

Acetylsalicylic acid (Aspirin) 500mg tab 33,142.41 3,998,407 0.01 1.17 81.14 BM1

Methyldopa 250mg Tab 30,736.77 1,211,225 0.03 1.09 82.22 BM10

Sulfamethoxazole 200mg+Trimethoprim 40mg/5ml 50ml Susp (Co-trimoxazole)

30,045.49 124,876 0.24 1.06 83.29 BM9

Ampicillin 500mg vial 29,803.43 219,115 0.13 1.05 84.34 BM3

Ketamin 50mg/ml 10ml Vial 29,753.78 17,072 1.43 1.05 85.39 BH9

Norgestrel 0.03mg Cycle 28,982.31 103,099 0.27 1.03 86.42 BM11

23

Page 29: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg Cycle

27,721.77 222,513 0.11 0.98 87.40 BM11

Amoxicillin 125mg/5ml, in 60ml bottle, susp 25,640.01 68,566 0.38 0.91 88.30 BM3

Paracetamol 100mg Tab 25,155.15 7,850,113 0.00 0.89 89.19 BM1

Mebendazole 100mg Tab 24,368.37 2,361,043 0.01 0.86 90.06 BM2

Ethinylestradiol 0.03mg+Norgestrel 0.3mg Cycle

18,473.46 87,520 0.15 0.65 90.71 BM11

Morphine (sulfate,hydrochloride) 10mg/ml, in 1ml Amp

17,425.17 6,401 1.94 0.62 91.33 BH12

Oxytocine 10IU/ml in 1ml Amp 17,328.19 170,085 0.10 0.61 91.94 BM18

Fluoxetine 20mg Cap 16,595.02 426,947 0.04 0.59 92.53 BM21

Gentamicin 20mg/ml, 2ml Amp 15,669.20 168,212 0.08 0.55 93.08 BH7

Sodium Chloride 0.9% 500ml IV infusion (Normal Saline)

12,629.91 22,262 0.47 0.45 93.53 BH21

Ergometrine 0.2mg Tab 11,138.83 564,060 0.02 0.39 93.92 BH5

Amitriptylline 25mg tab 8,909.55 1,155,356 0.01 0.32 94.24 BM21

Hydralazine 20mg/ml, in 2ml , Amp 8,824.19 17,465 0.86 0.31 94.55 BH14, M10

Artesunate 100mg+Pyrimethamine 25mg+ Sulfadoxine 500mg Blister

8,721.40 6,554 1.25 0.31 94.86 BH1, M20

Artesunate 50mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

8,556.96 13,003 0.74 0.30 95.16 CH1, M20

Gentamicin 10mg/ml, 2ml Amp 8,418.96 151,981 0.06 0.30 95.46 CH7

Penicillin Benzyl (Peni G crystal) 5MU Vial 7,810.55 30,011 0.22 0.28 95.73 CH3

Chloroquine 150mg Tab 7,582.08 727,796 0.01 0.27 96.00 CM19

24

Page 30: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Magnesium Sulfate 500mg/ml (50%) 10ml Amp

7,537.48 29,374 0.39 0.27 96.27 CH11

Rifampicin 150mg+Isoniazid 75mg+Pyrazinamide 400mg+Ethambutol 275mg (RHZE) per Tab

7,287.67 94,783 0.05 0.26 96.52 CM5

Chloroquine 50mg/5ml 60ml Syr 6,716.13 21,759 0.30 0.24 96.76 CM19

Ergometrine 0.2mg/ml, 1ml Amp 5,823.53 80,612 0.07 0.21 96.97 CH5

Nifedipine 10mg Tab/Cap 5,534.16 216,774 0.03 0.20 97.16 CM10

Salbutamol 0.05mg/ml (50mcg/ml) in 5ml Amp

5,345.86 22,159 0.21 0.19 97.35 CH20

Retinol (Vit A) 100,000 IU Tab 4,957.01 116,864 0.03 0.18 97.53 CM16

Metronidazole 120mg/5ml, in 100ml bottle, Susp

4,603.88 22,138 0.21 0.16 97.69 CM8

Atenolol 50mg Tab 4,476.98 370,799 0.01 0.16 97.85 CM10

Naloxone 400mcg/ml (0.4mg/ml) in 1ml Amp

3,898.60 10,091 0.41 0.14 97.99 CH13

Lidocaine 2% in 20ml Vial 3,845.09 7,788 0.43 0.14 98.12 CM7

Furosemide 10mg/ml, in 2ml Amp 3,618.23 48,319 0.05 0.13 98.25 CH6, M10

Quinine dihydrochloride 300mg/ml, in 2ml Amp

3,609.21 7,865 0.34 0.13 98.38 CH17

Rifampicin 150mg+Isoniazid 75mg (RH) Tab 2,367.54 149,693 0.01 0.08 98.46 CM5

Hydrochlorothiazide 50mg Tab 2,323.90 384,877 0.01 0.08 98.55 CM10

Diazepam 5mg/ml 2ml Amp 2,148.91 23,305 0.10 0.08 98.62 CM6

Ranitidine 25mg/ml, in 2ml Amp 2,129.54 13,287 0.15 0.08 98.70 CH18

25

Page 31: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Atenolol 100mg Tab 2,117.20 103,870 0.03 0.07 98.77 CM10

Sulfamethoxazole 400mg+Trimethoprim 80mg 50ml Susp (Co-trimoxazole)

2,057.52 106,311 0.22 0.07 98.84 CM9

Methylergometrine 0.125mg Tab 2,026.45 132,031 0.01 0.07 98.92 CH5

Atropine sulfate 1mg/ml, in 1ml Amp 1,964.88 32,308 0.06 0.07 98.99 CH2

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.5mg Tab

1,883.75 64,125 0.03 0.07 99.05 CM17

Artesunate 300mg+Pyrimethamine 25mg+Sulfadoxine 1000mg Blister

1,849.03 2,688 0.48 0.07 99.12 CH1, M20

Acetylsalicylic acid (Aspirin) 100mg tab 1,769.83 546,911 0.00 0.06 99.18 CM1

Ampicillin 500mg Tab 1,589.77 40,000 0.04 0.06 99.24 CM3

Acetylsalicylic acid (Aspirin) 300mg tab 1,581.97 170,664 0.01 0.06 99.29 CM1

Artesunate 150mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

1,468.25 4,642 0.51 0.05 99.34 CH1, M20

Rifampicin 150mg+Isoniazid 75mg+Ethambutol 275mg (RHE) Tab

1,262.01 19,428 0.04 0.04 99.39 CM5

Retinol (Vit A) 50,000IU Cap 1,223.06 23,782 0.04 0.04 99.43 CM16

Metronidazole 200mg/5ml, in 60ml bottle, Susp

1,176.40 3,775 0.33 0.04 99.47 CM8

Lidocaine 1% in 2ml Amp 1,167.96 4,168 0.20 0.04 99.51 CM7

Artesunate 600mg+Pyrimethamine 75mg+ Sulfadoxine 1500mg Blister

1,061.22 1,344 0.47 0.04 99.55 CH1, M20

Phenobarbital 100mg/ml, in 2ml Amp 1,045.48 2,398 0.40 0.04 99.59 CH16

Ethinylestradiol 0.035mg+Norethisterone 1mg Cycle

995.96 9,606 0.15 0.04 99.62 CM11

26

Page 32: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Norgestrel 0.075mg Cycle 931.08 5,252 0.10 0.03 99.66 CM11

Methylergometrine 0.2mg/ml, 1ml Amp 909.34 14,231 0.06 0.03 99.69 CH5

Furosemide 40mg Tab 864.13 83,047 0.01 0.03 99.72 CM10

Magnesium Sulfate 500mg/ml (50%) 20ml Amp

772.15 1,444 0.46 0.03 99.75 CH11

Lidocaine 5% 2ml Amp 765.71 4,134 0.13 0.03 99.77 CH10

Furosemide 20mg Tab 704.29 39,380 0.01 0.02 99.80 CM10

Phenobarbital 200mg/ml, 1ml Amp 562.41 2,046 0.29 0.02 99.82 CH16

Isoniazid 100mg Tab (INH) 512.84 8,541 0.04 0.02 99.84 CM4

Rifampicin 60mg+Isoniazid 30mg (RH) Tab 504.63 12,551 0.02 0.02 99.86 CM5

Digoxin 0.25mg Tab 484.49 29,169 0.02 0.02 99.87 CH4

Digoxin 0.25mg/ml 2ml Amp 472.85 2,065 0.17 0.02 99.89 CH4

Salbutamol 0.5mg/ml, in 1ml Amp 384.74 2,722 0.16 0.01 99.90 CH20

Nifedipine 20mg Tab/Cap 366.47 20,534 0.02 0.01 99.92 CM10

Propranolol 40mg Tab 309.37 28,481 0.01 0.01 99.93 CM10

Rifampicin 60mg+Isoniazid 30mg+Pyrazinamide 150mg (RHZ) Tab

307.49 5,652 0.03 0.01 99.94 CM5

Hydrochlorothiazide 25mg Tab 270.27 16,841 0.01 0.01 99.95 CM10

Phenobarbital 50mg/ml 5ml Amp 261.22 754 0.29 0.01 99.96 CH16

Captopril 25mg Tab 192.57 10,864 0.03 0.01 99.96 CM10

27

Page 33: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Paracetamol 325mg Tab 157.87 22,840 0.01 0.01 99.97 CM1

Retinol (Vit A) 100,000 IU Amp 154.90 3,488 0.04 0.01 99.97 CM16

Lidocaine 1% 50ml Vial 122.34 354 0.35 0.00 99.98 CM7

Lidocaine 2% in 50ml Vial 118.40 302 0.38 0.00 99.98 CM7

Amitriptylline 10mg tab 113.36 8,200 0.01 0.00 99.99 CM21

Paracetamol 100mg/ml, 15ml Drop 85.54 330 0.24 0.00 99.99 CM1

Penicillin Benzyl (Peni G crystal) 1MU Vial 72.42 296 0.12 0.00 99.99 CH3

Pethidine 100mg/ml, 1ml Amp 52.78 1,514 0.01 0.00 99.99 CH15

Atenolol 25mg Tab 42.20 1,221 0.03 0.00 100.00 CM10

Propranolol 10mg Tab 26.65 1,580 0.01 0.00 100.00 CM10

Chloroquine 250mg Tab 26.25 2,202 0.01 0.00 100.00 CM19

Lidocaine 1% 20ml Vial 21.60 50 0.43 0.00 100.00 CM7

Chloroquine 40mg/ml, in 5ml Amp 20.48 165 0.08 0.00 100.00 CM19

Rifampicin 300mg Tab 8.57 496 0.02 0.00 100.00 CM5

Atropine Sulfate 1% in 5ml bottle, ophthalmic drop

7.07 136 0.06 0.00 100.00 CH2

Chloroquine 100mg Tab 4.47 490 0.01 0.00 100.00 CM19

Fluoxetine 10mg Tab 1.90 50 0.04 0.00 100.00 CM21

Metoprolol 1mg/ml, in 5ml Amp 0.00 0 0.21 0.00 100.00 CM10

28

Page 34: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines HMIS Code Total Conumed Value at all HFs in US$

Total Consumed Quantity

Average Unit Pricein US$

% of the Value % of Cumulative Value

Class

Zinc Sulfate 10mg Tab 0.00 0 0.00 0.00 100.00 CM15

Spironolactone 100mg Tab 0.00 0 0.00 0.00 100.00 CM10

Hydralazine 50mg Tab 0.00 0 0.00 0.00 100.00 CM10

Isoniazid 300mg Tab (INH) 0.00 0 0.01 0.00 100.00 CM4

Ethinylestradiol 0.05mg+Levonorgestrel 0.25mg Cycle

0.00 0 0.03 0.00 100.00 CM11

Paracetamol (Acetaminophen) 225mg/3ml, Amp (75mg/ml)

0.00 0 0.16 0.00 100.00 CM1

Retinol (Vit A) 25,000IU Cap 0.00 0 0.03 0.00 100.00 CM16

Mebendazole 500mg Tab 0.00 0 0.00 0.00 100.00 CM2

Metronidazole 250mg Tab 0.00 0 0.01 0.00 100.00 CM8

Propranolol 20mg Tab 0.00 0 0.01 0.00 100.00 CM10

Metronidazole 500mg Tab 0.00 0 0.00 0.00 100.00 CM8

Hydralazine 25mg Tab 0.00 0 0.00 0.00 100.00 CM10

Pethidine 50mg/ml, 2ml Amp 0.00 0 0.09 0.00 100.00 CH15

Lidocaine 20mg/ml 5ml Amp 0.00 0 0.35 0.00 100.00 CM7

29

Page 35: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 4A. Quarterly Public Expenditures on Medicines per Patient/Client at BPHS/EPHS, by Province

3Quarter , 1393 (Mizan - Qaws)

This table shows the quarterly public expenditure on medicines per patient/client at the BPHS/EPHS level in the provinces. It was between US$0.11 (Kabul) and US$0.77 (Ghor) with the overall average of US$0.32. This information reveals that quarterly public expenditure on medicines per patient/client at the BPHS/EPHS level is very low. The total number of patients/clients was obtained from HMIS data for the same quarter.

Province Total Patients/clients Value of Medicines Consumed in US$

Average Medicine Expenditure in US$

Badakhshan 550,675 120,511.52 0.22

Badghis 231,165 25,459.10 0.11

Baghlan 486,784 113,863.94 0.23

Balkh 699,188 102,991.78 0.15

Bamyan 306,552 72,615.36 0.24

Dykundi 236,713 143,504.90 0.61

Farah 249,845 61,850.02 0.25

Faryab 484,171 119,324.43 0.25

Ghazni 467,046 140,842.05 0.30

Ghor 306,778 235,238.19 0.77

Helmand 537,059 181,404.60 0.34

Hirat 817,733 186,555.36 0.23

Jawzjan 323,016 59,647.00 0.18

Kabul 1,342,201 144,187.28 0.11

Kandahar 508,126 66,512.75 0.13

Khost 303,501 83,923.19 0.28

Kunar 396,530 198,408.03 0.50

Kunduz 354,341 51,347.35 0.14

Laghman 320,801 198,342.23 0.62

Logar 267,208 116,655.59 0.44

Nangarhar 1,083,284 395,001.40 0.36

Nimroz 115,393 18,054.86 0.16

Nooristan 65,441 49,827.50 0.76

Paktika 208,937 56,618.69 0.27

Paktya 325,089 89,631.99 0.28

Samangan 215,895 46,225.60 0.21

Sar-e-Pul 285,893 62,821.04 0.22

*Definition of "Total Patient/client": total number of new, <5, >5, male and female and revisits of out-patients and in-patients. Source: National Health Management Information System Procedures Manual Section III, Annex 2, Indicator 65. 30

Page 36: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Province Total Patients/clients Value of Medicines Consumed in US$

Average Medicine Expenditure in US$

Takhar 468,171 111,508.77 0.24

Urozgan 267,366 135,273.19 0.51

Wardak 291,831 130,740.94 0.45

Zabul 113,253 45,392.52 0.40

Overall 12,629,986 3,564,281.16 0.32

*Definition of "Total Patient/client": total number of new, <5, >5, male and female and revisits of out-patients and in-patients. Source: National Health Management Information System Procedures Manual Section III, Annex 2, Indicator 65. 31

Page 37: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 4B. Quarterly Public Expenditures on Medicines per Capita at BPHS/EPHS, by Province

3Quarter , 1393 (Mizan - Qaws)

This table reflects the quarterly public expenditure on medicines per capita at the BPHS/EPHS level in the provinces. It was between US$0.04(Kabul) and US$0.47 (Laghman). With the overall average of US$0.19. Estimated population data are obtained from the latest update of Afghanistan’s Central Statistics Office.

Province Population Value of Medicines Consumed in US$ Average Medicine Expenditure in US$

Badakhshan 904,700 120,511.52 0.13

Badghis 471,900 25,459.10 0.05

Baghlan 863,700 113,863.94 0.13

Balkh 1,245,100 102,991.78 0.08

Bamyan 425,500 72,615.36 0.17

Dykundi 438,500 143,504.90 0.33

Farah 482,400 61,850.02 0.13

Faryab 948,000 119,324.43 0.13

Ghazni 1,168,800 140,842.05 0.12

Ghor 657,200 235,238.19 0.36

Helmand 879,500 181,404.60 0.21

Hirat 1,780,000 186,555.36 0.10

Jawzjan 512,100 59,647.00 0.12

Kabul 3,950,300 144,187.28 0.04

Kandahar 1,151,100 66,512.75 0.06

Khost 546,800 83,923.19 0.15

Kunar 428,800 198,408.03 0.46

Kunduz 953,800 51,347.35 0.05

Laghman 424,100 198,342.23 0.47

Logar 373,100 116,655.59 0.31

Nangarhar 1,436,000 395,001.40 0.28

Nimroz 156,600 18,054.86 0.12

Nooristan 140,900 49,827.50 0.35

Paktika 413,800 56,618.69 0.14

Paktya 525,000 89,631.99 0.17

Samangan 368,800 46,225.60 0.13

Sar-e-Pul 532,000 62,821.04 0.12

Takhar 933,700 111,508.77 0.12

Urozgan 333,500 135,273.19 0.41

* Estimated population data for 2012-2013 from the Afghanistan’s Central Statistics Office (CSO) http://cso.gov.af/Content/files/Settled%20Population%20by%20Civil%20Division,.pdf

32

Page 38: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Province Population Value of Medicines Consumed in US$ Average Medicine Expenditure in US$

Wardak 567,600 130,740.94 0.23

Zabul 289,300 45,392.52 0.16

Overall 24,302,600 3,564,281.16 0.19

* Estimated population data for 2012-2013 from the Afghanistan’s Central Statistics Office (CSO) http://cso.gov.af/Content/files/Settled%20Population%20by%20Civil%20Division,.pdf

33

Page 39: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 5A. Average HF Days of Stock-out for Each Medicine 3Quarter , 1393 (Mizan - Qaws)

This table shows the average days of stock-out of each medicine among health facilities. The current version of PLIS is not able to provide the exact number of days of medicine stock-outs within HFs. This table is to provide highlights of the general extent of stock-out of the medicines within HFs.

Medicine Name Total Days of Stock out Total HFs Average Days

Acetylsalicylic acid (Aspirin) 100mg tab 851 1549 0.55

Acetylsalicylic acid (Aspirin) 500mg tab 741 1549 0.48

Activated charcoal 125mg tab 67 1549 0.04

Activated charcoal 250mg tab 1008 1549 0.65

Adrenalin 0.0005%+Lidocaine 2% in 50ml vial 200 1549 0.13

Adrenalin 0.00125%+Lidocaine dental 1% Amp 156 1549 0.10

Adrenalin 1:200,000 (0.0005%)+Lidocaine 1% Amp 207 1549 0.13

Albendazole 400mg tab 78 1549 0.05

Alcuronium Injection, 5mg/ml in 2ml Amp 108 1549 0.07

Alprazolam 0.5mg tab 78 1549 0.05

Aluminium hydroxide 200mg+Magnesium hydroxide 200mg tab

569 1549 0.37

Aluminium hydroxide 225mg+Magnesium hydroxide 200mg/5ml, 200ml/bottle, susp

3453 1549 2.23

Aluminium hydroxide 500mg tab 613 1549 0.40

Aminophylline 100mg tab 696 1549 0.45

Aminophylline 25mg/ml, in 10ml Amp 331 1549 0.21

Amitriptylline 25mg tab 653 1549 0.42

Amoxicillin 125mg/5ml, in 60ml bottle, susp 123 1549 0.08

Amoxicillin 250mg Cap 368 1549 0.24

Amoxicillin 250mg/5ml, in 60ml bottle, Susp 361 1549 0.23

Amoxicillin 500mg Cap 377 1549 0.24

Ampicillin 1g vial 944 1549 0.61

Ampicillin 500mg vial 920 1549 0.59

Antitetanus Immunoglobulin 1500IU/1ml, in 1ml Amp

276 1549 0.18

Artemether 20mg/ml, 1ml Amp 595 1549 0.38

Artemether 80mg/ml, 1ml, Amp 313 1549 0.20

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.34

Page 40: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Artesunate 100mg+Pyrimethamine 25mg+ Sulfadoxine 500mg Blister

11 1549 0.01

Artesunate 150mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

552 1549 0.36

Artesunate 300mg+Pyrimethamine 25mg+Sulfadoxine 1000mg Blister

251 1549 0.16

Artesunate 50mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

91 1549 0.06

Artesunate 600mg+Pyrimethamine 75mg+ Sulfadoxine 1500mg Blister

659 1549 0.43

Atenolol 100mg Tab 362 1549 0.23

Atenolol 50mg Tab 287 1549 0.19

Atropine sulfate 1mg/ml, in 1ml Amp 129 1549 0.08

Bacitracin 500IU+Neomycin 5mg/g, 15g topical Oint 61 1549 0.04

Benzoic Acid 6%+Salicylic acid 3% topical Oint 1302 1549 0.84

Benzyl benzoate 25% in 60ml bottle, topical lotion 90 1549 0.06

Betamethasone 0.1%+Neomycine 0.5% in 10ml bottle, ophthalmic drop

801 1549 0.52

Bupivacaine 0.5% in 10ml Amp 90 1549 0.06

Bupivacaine 0.5% in 20ml Amp 90 1549 0.06

Bupivacaine 5mg/ml, 4ml Amp 78 1549 0.05

Calamine (ZnO + Fe2O3) 8% in 60ml bottle, topical lotion

90 1549 0.06

Calcium Gluconate 10% 10ml Amp 134 1549 0.09

Calcium Lactate 300mg Tab 90 1549 0.06

Captopril 25mg Tab 90 1549 0.06

Carbamazepine 200mg Tab 107 1549 0.07

Ceftriaxone 1g Vial 100 1549 0.06

Ceftriaxone 500mg Vial 208 1549 0.13

Cetrimide 15%+Chlorhexidine gluconate 1.5% topical Sol

296 1549 0.19

Chloramphenicol 0.5% in 2.5ml bottle, ophthalmic drop

105 1549 0.07

Chloramphenicol 0.5%+Dexamethasone 0.1% in 2.5ml bottle, ophthalmic drop

10 1549 0.01

Chloramphenicol 125mg/5ml 100ml Bottle Susp 528 1549 0.34

Chloramphenicol 1g Vial 877 1549 0.57

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.35

Page 41: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Chloramphenicol 250mg Cap 1157 1549 0.75

Chlorhexidine Digluconate 5% Topical Sol 1004 1549 0.65

Chloroquine 100mg Tab 90 1549 0.06

Chloroquine 150mg Tab 82 1549 0.05

Chloroquine 40mg/ml, in 5ml Amp 90 1549 0.06

Chloroquine 50mg/5ml 60ml Syr 197 1549 0.13

Chloroxylenol 4.8% , topical Sol 90 1549 0.06

Chlorphenamine maleate 10mg/ml , in 1ml Amp 607 1549 0.39

Chlorphenamine maleate 4mg Tab 809 1549 0.52

Chlorpromazine 100mg Tab 615 1549 0.40

Chlorpromazine 25mg/ml, 2ml Amp 740 1549 0.48

Chlorpromazine 50mg/ml, 2ml Amp 58 1549 0.04

Cimetidine 100mg/ml 2ml Amp 90 1549 0.06

Cimetidine 200mg Tab 90 1549 0.06

Ciprofloxacin 250mg Tab 234 1549 0.15

Ciprofloxacin 500mg Tab 168 1549 0.11

Cloxacillin 250mg Cap 95 1549 0.06

Cloxacillin 500mg Cap 76 1549 0.05

Cloxacillin 500mg Vial 78 1549 0.05

Condom 246 1549 0.16

Dexamethasone 4mg /ml 1ml Amp 90 1549 0.06

Diazepam 10mg Tab 473 1549 0.31

Diazepam 5mg Tab 318 1549 0.21

Diazepam 5mg/ml 2ml Amp 1032 1549 0.67

Diclofenac 25mg/ml 3ml Amp 631 1549 0.41

Diclofenac 75mg Tab 90 1549 0.06

Diethylcarbamazine citrate 50mg Tab 168 1549 0.11

Digoxin 0.25mg/ml 2ml Amp 8 1549 0.01

Diphenhydramine chloride 5mg/5ml, 60ml, Syr 120 1549 0.08

Dopamine 40mg/ml 5ml Amp 90 1549 0.06

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.36

Page 42: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Doxycycline 100mg Cap 309 1549 0.20

Ephedrine Hcl 3mg/ml, in 10ml , Amp 116 1549 0.07

Epinephrine (Adrenaline) 0.1% in 1ml Amp 509 1549 0.33

Ergometrine 0.2mg Tab 555 1549 0.36

Ergometrine 0.2mg/ml, 1ml Amp 278 1549 0.18

Erythromycin (Base) 200mg/5ml, in 60ml, susp 190 1549 0.12

Erythromycin (Ethyl Succinate) 100mg/ml 100ml Susp

127 1549 0.08

Erythromycin Stearate 250mg Tab 21 1549 0.01

Erythromycin Stearate 500mg Tab 92 1549 0.06

Ethambutol (EMB) 400mg Tab 584 1549 0.38

Ethambutol 400mg+Isoniazid 150mg Tab (EH) 652 1549 0.42

Ethanol 70% topical solution 90 1549 0.06

Ethinylestradiol 0.035mg+Norethisterone 1mg Cycle 4372 1549 2.82

Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg Cycle

204 1549 0.13

Ethinylestradiol 0.03mg+Norgestrel 0.3mg Cycle 90 1549 0.06

Ethinylestradiol 0.05mg+Levonorgestrel 0.25mg Cycle

4418 1549 2.85

Ferrous Sulfate 25mg/ml 120ml Drop 1357 1549 0.88

Ferrous Sulfate 60mg Tab 700 1549 0.45

Ferrous Sulphate 200mg Tab 761 1549 0.49

Ferrous Sulphate 60mg+Folic Acid 0.4mg Tab 568 1549 0.37

Fluoxetine 20mg Cap 212 1549 0.14

Folic Acid 1mg Tab 138 1549 0.09

Folic Acid 5mg Tab 294 1549 0.19

Furosemide 10mg/ml, in 2ml Amp 197200 1549 127.31

Furosemide 20mg Tab 231 1549 0.15

Furosemide 40mg Tab 189 1549 0.12

Gentamicin 0.3% in 5ml bottle, ophthalmic drop 10 1549 0.01

Gentamicin 10mg/ml, 2ml Amp 503 1549 0.32

Gentamicin 40mg/ml, 2ml Amp 344 1549 0.22

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.37

Page 43: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Glibenclamide 5mg Tab 442 1549 0.29

Glocuse 2.5% + Sodium chloride 0.45% 1000ml 90 1549 0.06

Glucose 10% 500ml IV infusion 660 1549 0.43

Glucose 4%+Sodium Chloride 0.18% 500ml IV infusion

1478 1549 0.95

Glucose 5% 1000ml IV infusion 462 1549 0.30

Glucose 5% 500ml IV infusion 440 1549 0.28

Glucose 5%+Sodium Chloride 0.9% 1000ml IV infusion

410 1549 0.26

Glucose 5%+Sodium Chloride 0.9% 500ml IV infusion 317 1549 0.20

Glucose 50% 50ml IV 424 1549 0.27

Glyceryl trinitrate (Nitroglycerine) 0.5mg per tablet, sublingual-oral tablet

90 1549 0.06

Griseofulvin 125mg Tab 442 1549 0.29

Haloperidol 5mg Tab 50 1549 0.03

Haloperidol 5mg/ml, 1ml Amp 378 1549 0.24

Heparin 25000IU/ml 1ml Amp 120 1549 0.08

Hydralazine 20mg/ml, in 2ml , Amp 284 1549 0.18

Hydralazine 25mg Tab 90 1549 0.06

Hydralazine 50mg Tab 90 1549 0.06

Hydrochlorothiazide 25mg Tab 90 1549 0.06

Hydrochlorothiazide 50mg Tab 314 1549 0.20

Hydrocortisone Acetate 1% 15g Oint 90 1549 0.06

Hydrocortisone Sodium Succinate 100mg Vial 516 1549 0.33

Hydrogen peroxide 6% topical Solution 364 1549 0.23

Hyoscine (butylbromide,hydrobromide) 10mg Tab 112 1549 0.07

Ibuprofen 200mg Tab 1415 1549 0.91

Ibuprofen 400 mg Tab 109 1549 0.07

Insulin (70/30) 100 IU/ml, 10ml Vial 93 1549 0.06

Intrauterine device (IUD) with copper 1pce , vaginal intra uterine device

5 1549 0.00

Iodine 200mg Cap 772 1549 0.50

Iodine 540mg/ml, in 0.57ml bottle 772 1549 0.50

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.38

Page 44: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Isoniazid 100mg Tab (INH) 234 1549 0.15

Isoniazid 300mg Tab (INH) 90 1549 0.06

Isosorbide Dinitrate 5mg Tab 475 1549 0.31

Ketoconazole 2% 15g Oint 10 1549 0.01

Ketoconazole 200mg Tab 952 1549 0.61

Lidocaine 1% 20ml Vial 90 1549 0.06

Lidocaine 1% in 2ml Amp 495 1549 0.32

Lidocaine 2% in 15g tube, topical gel 304 1549 0.20

Lidocaine 2% in 20ml Vial 65 1549 0.04

Lidocaine 4% cream/Oint 981 1549 0.63

Lidocaine 5% 2ml Amp 190 1549 0.12

Lindane 1% in 100ml bottle, topical lotion 116 1549 0.07

Magnesium Sulfate 500mg/ml (50%) 10ml Amp 178 1549 0.11

Mebendazole 100mg Tab 594 1549 0.38

Medroxyprogesterone acetate Depot 150mg/ml, in 1ml vial

526 1549 0.34

Meglumine antimoniate 30%, 5ml Amp (Meglusan 1.5g, 8.1% antimony)

25 1549 0.02

Metformin 500mg Tab 83 1549 0.05

Methyldopa 250mg Tab 791 1549 0.51

Methylrosaniline (Gentian Violet) 0.5% in 10ml bottle, topical Sol

846 1549 0.55

Methylrosaniline (Gentian Violet) 1% in 10ml bottle, topical Sol

474 1549 0.31

Metoclopramide 10mg Tab 585 1549 0.38

Metoclopramide 5mg/ml, in 2ml Amp 338 1549 0.22

Metronidazole 200mg Tab 700 1549 0.45

Metronidazole 200mg/5ml, in 100ml bottle, Susp 583 1549 0.38

Metronidazole 200mg/5ml, in 60ml bottle, Susp 22 1549 0.01

Metronidazole 400mg Tab 459 1549 0.30

Metronidazole 5mg/ml, in 100ml bottle, infusion Sol 20 1549 0.01

Miconazole 2% in 30g , topical Oint 90 1549 0.06

Misoprostol 200mcg Tab 78 1549 0.05

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.39

Page 45: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Morphine (sulfate,hydrochloride) 10mg/ml, in 1ml Amp

78 1549 0.05

Multivitamin Tab 1117 1549 0.72

Naloxone 400mcg/ml (0.4mg/ml) in 1ml Amp 28 1549 0.02

Nifedipine 10mg Tab/Cap 230 1549 0.15

Nitrofurantoin 100mg Tab/Cap 608 1549 0.39

Norethindrone 0.35mg (Progestin-Only Pills or Mini-Pills)

4345 1549 2.81

Norgestrel 0.03mg Cycle 138 1549 0.09

Norgestrel 0.075mg Cycle 90 1549 0.06

Nystatin 100,000IU 15g Vaginal Oint 1150 1549 0.74

Nystatin 100,000IU 30ml Oral Topical Drop 1156 1549 0.75

Nystatin 100,000IU Oral Tab 1400 1549 0.90

Nystatin 100,000IU Vaginal Tab/ovule suppository 248 1549 0.16

Nystatin 500,000IU Tab, oral 715 1549 0.46

Omeprazole 20mg Cap 146 1549 0.09

Oral rehydration salts (ORS , Resomal and low osmolar) 20.5g/Lit

448 1549 0.29

Oral rehydration salts (ORS , Resomal and low osmolar) 27.9g/Lit

102 1549 0.07

Oxytocine 10IU/ml in 1ml Amp 160 1549 0.10

Pancuronium Bromide (Pavulon) 2mg/ml, 2ml Amp 90 1549 0.06

Paracetamol 100mg Tab 458 1549 0.30

Paracetamol 120mg/5ml, 60ml Syr 416 1549 0.27

Paracetamol 500mg Tab 513 1549 0.33

Paraffin liquid in 10ml oral 90 1549 0.06

Penicillin Benzyl (Peni G crystal) 1MU Vial 858 1549 0.55

Penicillin Benzyl (Peni G crystal) 5MU Vial 858 1549 0.55

Penicillin Benzyl Benzathine 1.2MU Vial 233 1549 0.15

Penicillin Benzyl Benzathine 2.4MU Vial 584 1549 0.38

Penicillin Benzyl Procaine 2MU Vial 482 1549 0.31

Penicillin Benzyl Procaine 4MU Vial 417 1549 0.27

Penicillin V Potassium 250mg Tab 350 1549 0.23

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.40

Page 46: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Penicillin V Potassium 500mg Tab 581 1549 0.38

Penicillin V(Phenoxy methyl Penicillin) 125mg/5ml, in 100ml bottle, Susp

90 1549 0.06

Penicillin V(Phenoxy methyl Penicillin) 250mg/5ml, in 100ml bottle, Susp

250 1549 0.16

Pethidine 100mg Tab 78 1549 0.05

Pethidine 100mg/ml, 1ml Amp 90 1549 0.06

Pethidine 50mg Tab 78 1549 0.05

Pethidine 50mg/ml, 2ml Amp 78 1549 0.05

Phenobarbital 100mg Tab 797 1549 0.51

Phenobarbital 15mg Tab 316 1549 0.20

Phenobarbital 50mg/ml 5ml Amp 78 1549 0.05

Phytomenadione (Vit K) 10mg Tab 26 1549 0.02

Phytomenadione (Vit K) 10mg/2ml, Amp 71 1549 0.05

Phytomenadione (Vit K) 10mg/ml, 5ml Amp (50mg/5ml)

496 1549 0.32

Polymyxin 10000IU+Bacitracin 500IU per gram, in 6g tube, ophthalmic oint

2 1549 0.00

Potassium Chloride 10% 10ml Amp 90 1549 0.06

Potassium Chloride 11.2% 20ml Amp 208 1549 0.13

Potassium permanganate powder 78 1549 0.05

Povidone-Iodine 10% Topical Sol 167 1549 0.11

Precipitated Sulfur Powder 90 1549 0.06

Prednisolone 5mg Tab 128 1549 0.08

Primaquine 15mg Tab 116 1549 0.07

Propofol 10mg/ml 20ml Infusion Sol 90 1549 0.06

Propranolol 10mg Tab 506 1549 0.33

Propranolol 40mg Tab 596 1549 0.38

Protamine Sulfate 10mg/ml 5ml Amp 78 1549 0.05

Pyrazinamide (PZA) 500mg Tab 4367 1549 2.82

Pyrimethamine 25mg+Sulfadoxine 500mg Tab 104 1549 0.07

Quinine dihydrochloride 300mg/ml, in 2ml Amp 219 1549 0.14

Quinine Sulfate 300mg Tab 489 1549 0.32

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.41

Page 47: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Ranitidine 150mg Tab 644 1549 0.42

Ranitidine 25mg/ml, in 2ml Amp 90 1549 0.06

Ranitidine 300mg Tab 206 1549 0.13

Retinol (Vit A) 100,000 IU Amp 740 1549 0.48

Retinol (Vit A) 100,000 IU Tab 91 1549 0.06

Retinol (Vit A) 200,000 IU Cap 165 1549 0.11

Retinol (Vit A) 50,000IU Cap 90 1549 0.06

Rifampicin 150mg+Isoniazid 75mg (RH) Tab 390 1549 0.25

Rifampicin 150mg+Isoniazid 75mg+Ethambutol 275mg (RHE) Tab

314 1549 0.20

Rifampicin 150mg+Isoniazid 75mg+Pyrazinamide 400mg+Ethambutol 275mg (RHZE) per Tab

260 1549 0.17

Rifampicin 60mg+Isoniazid 30mg (RH) Tab 543 1549 0.35

Rifampicin 60mg+Isoniazid 30mg+Pyrazinamide 150mg (RHZ) Tab

650 1549 0.42

Ringer lactate 1000ml IV infusion 226 1549 0.15

Ringer lactate 500ml IV infusion 661 1549 0.43

Salbutamol 0.05mg/ml (50mcg/ml) in 5ml Amp 607 1549 0.39

Salbutamol 0.1mg/dose 200 dose Bottle Inhalation Sol

602 1549 0.39

Salbutamol 0.5mg/ml, in 1ml Amp 5 1549 0.00

Salbutamol 2mg Tab 90 1549 0.06

Salbutamol 2mg/5ml, in 60ml bottle, Syr 361 1549 0.23

Salbutamol 4mg Tab 499 1549 0.32

Salbutamol 5mg/ml in 30ml Inhalation Sol 218 1549 0.14

Salicylic Acid 5% Oint 78 1549 0.05

Silver sulfadiazine 1% in 250g container, topical cream

10 1549 0.01

Silver Sulfadiazine 1% Oint 181 1549 0.12

Sodium Bicarbonate 8.4% 10ml Amp 421 1549 0.27

Sodium Chloride 0.9% 1000ml IV infusion (Normal Saline)

69 1549 0.04

Sodium Chloride 0.9% 500ml IV infusion (Normal Saline)

90 1549 0.06

Sodium Citrate Powder 90 1549 0.06

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.42

Page 48: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicine Name Total Days of Stock out Total HFs Average Days

Sodium Stibogluconate 100mg/ml, 30ml Vial 527 1549 0.34

Streptomycin 1g Vial 104 1549 0.07

Sulfamethoxazole 100mg+Trimethoprim 20mg Tab (Co-trimoxazole)

227 1549 0.15

Sulfamethoxazole 200mg+Trimethoprim 40mg/5ml 50ml Susp (Co-trimoxazole)

692 1549 0.45

Sulfamethoxazole 400mg+Trimethoprim 80mg 50ml Susp (Co-trimoxazole)

90 1549 0.06

Sulfamethoxazole 400mg+Trimethoprim 80mg Tab (Co-trimoxazole)

1236 1549 0.80

Sulphacetamide 20% 10ml Eye Drop 10 1549 0.01

Suxamethonium 50mg/ml 2ml Amp 37 1549 0.02

Tetracaine 0.5% 15ml Eye Drop 622 1549 0.40

Tetracycline Eye 1% Oint 731 1549 0.47

Thiopental Sodium 1g Vial 90 1549 0.06

Thiopental Sodium 500mg Vial 90 1549 0.06

Thioridazine 25mg Tab 156 1549 0.10

Tramadol 100mg/2ml, Amp 21 1549 0.01

Tramadol 50mg/ml, in 2ml Amp 60 1549 0.04

Trihexyphenidyl 2mg Tab 117 1549 0.08

Tuberculin Purified 10IU/ml, in 1ml Amp 78 1549 0.05

Water for Injection 10ml Amp 953 1549 0.62

Water for Injection 5ml Amp 272 1549 0.18

Zinc Oxide 10% 100g Oint 30 1549 0.02

Zinc Oxide 10% 20g Oint 90 1549 0.06

Zinc Oxide 20% 20g Oint 78 1549 0.05

Zinc Sulfate 20mg Tab 307 1549 0.20

Type of HFs include: RH, PH, DH, CHC, BHC, SHC, MHT and Other.43

Page 49: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Table 6. The Summary of the Overall Volume Indicators for HMIS Indicator Medicines

3Quarter ,1393 (Mizan - Qaws)

This table shows the summary of overall quantities (volume indicators) flow between the three levels of supply chain for HMIS indicator medicines. The data reveals that paracetamol 500mg tab had the highest consumed quantity (20,603,556 tabs) in the reporting quarter.

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Acetylsalicylic acid (Aspirin) 100mg tab 1,738,053 362,570 2,100,623 233,600 546,911 25,298 914,554

Acetylsalicylic acid (Aspirin) 300mg tab 777,260 280,300 1,057,560 0 170,664 0 117,130

Acetylsalicylic acid (Aspirin) 500mg tab 6,356,815 5,515,273 11,872,088 230,000 3,998,407 71,126 7,340,382

Amitriptylline 10mg tab 4,100 60,000 64,100 0 8,200 0 55,900

Amitriptylline 25mg tab 4,807,033 549,660 5,356,693 0 1,155,356 50,153 2,683,288

Amoxicillin 125mg/5ml, in 60ml bottle, susp 166,746 76,540 243,286 300 68,566 5,291 188,119

Amoxicillin 250mg Cap 11,820,257 6,762,800 18,583,057 75,000 6,261,244 7,375 14,644,298

Amoxicillin 250mg/5ml, in 60ml bottle, Susp 283,896 204,836 488,732 0 205,260 134 265,820

Amoxicillin 500mg Cap 11,371,062 9,190,968 20,562,030 0 8,661,255 296,681 14,243,942

Ampicillin 1g vial 437,156 232,603 669,759 0 233,786 25,379 482,537

Ampicillin 500mg Tab 6,000 100,000 106,000 0 40,000 0 66,000

Ampicillin 500mg vial 426,363 244,182 670,545 12,300 219,115 6,104 548,438

Artesunate 100mg+Pyrimethamine 25mg+ Sulfadoxine 500mg Blister

13,506 3,277 16,783 0 3,694 162 17,618

Artesunate 150mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

4,281 176 4,457 0 924 0 38,825

Artesunate 300mg+Pyrimethamine 25mg+Sulfadoxine 1000mg Blister

2,766 100 2,866 0 2,413 183 7,743

Artesunate 50mg+Pyrimethamine 25mg+Sulfadoxine 500mg Blister

50,171 489 50,660 0 4,860 69 47,345

Artesunate 600mg+Pyrimethamine 75mg+ Sulfadoxine 1500mg Blister

35,820 100 35,920 0 554 118 35,281

Atenolol 100mg Tab 210,664 71,220 281,884 0 103,870 16 277,758

44

Page 50: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Atenolol 25mg Tab 4,414 3,000 7,414 0 1,221 5 8,960

Atenolol 50mg Tab 634,019 330,296 964,315 0 370,799 44,667 681,796

Atropine Sulfate 1% in 5ml bottle, ophthalmic drop 0 0 0 0 0 0 0

Atropine sulfate 1mg/ml, in 1ml Amp 33,347 7,340 40,687 0 10,153 1,573 84,167

Captopril 25mg Tab 6,874 20,800 27,674 0 10,864 0 3,686

Chloroquine 100mg Tab 50 0 50 0 490 0 19,360

Chloroquine 150mg Tab 3,237,642 383,740 3,621,382 9,000 727,796 29,413 2,836,487

Chloroquine 250mg Tab 24,500 22,000 46,500 0 2,202 12,260 32,038

Chloroquine 40mg/ml, in 5ml Amp 440 0 440 0 165 0 343

Chloroquine 50mg/5ml 60ml Syr 168,603 3,897 172,500 0 21,759 2,012 136,960

Chloroquine Phosphate 300mg Tab 0 0 0 0 0 0 0

Condom 3,659,639 1,673,452 5,333,091 9,000 2,302,432 1,609 2,656,599

Diazepam 5mg/ml 2ml Amp 80,581 21,424 102,005 500 23,305 594 108,990

Digoxin 0.25mg Tab 48,842 2,825 51,667 0 4,188 1,960 42,239

Digoxin 0.25mg/ml 2ml Amp 5,656 270 5,926 0 693 178 4,790

Ergometrine 0.2mg Tab 1,014,726 147,190 1,161,916 0 169,795 37,432 995,053

Ergometrine 0.2mg/ml, 1ml Amp 83,798 18,549 102,347 0 27,512 730 150,684

Ethinylestradiol 0.035mg+Norethisterone 1mg Cycle 222,599 5,593 228,192 0 9,606 115 218,471

Ethinylestradiol 0.03mg+Levonorgestrel 0.15mg Cycle

792,854 205,461 998,315 0 222,513 51,502 885,295

Ethinylestradiol 0.03mg+Norgestrel 0.3mg Cycle 192,153 77,984 270,137 0 87,520 262 180,729

Ethinylestradiol 0.05mg+Levonorgestrel 0.25mg Cycle

0 0 0 0 0 0 0

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.25mg Tab 12,582,759 7,248,200 19,830,959 0 11,109,589 16,123 15,381,267

Ferrous sulfate 200mg+Folic acid (Vit B9) 0.5mg Tab 178,675 20,000 198,675 0 64,125 0 134,550

45

Page 51: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Ferrous Sulphate 60mg+Folic Acid 0.4mg Tab 22,598,079 6,982,353 29,580,432 1,130,000 10,918,658 216,524 12,200,436

Fluoxetine 10mg Tab 1,420 0 1,420 0 50 0 2,870

Fluoxetine 20mg Cap 1,362,889 550,080 1,912,969 0 426,947 26,000 1,511,797

Furosemide 10mg/ml, in 2ml Amp 63,617 5,399 69,016 0 15,739 961 62,008

Furosemide 20mg Tab 163,640 23,400 187,040 0 39,380 23,450 167,240

Furosemide 40mg Tab 292,689 84,710 377,399 0 83,047 5,097 227,629

Gentamicin 10mg/ml, 2ml Amp 428,369 50,270 478,639 100 44,528 2,061 475,964

Gentamicin 20mg/ml, 2ml Amp 173,066 52,245 225,311 0 52,147 20 197,163

Gentamicin 40mg/ml, 2ml Amp 234,151 112,771 346,922 0 104,798 10,123 304,283

Hydralazine 20mg/ml, in 2ml , Amp 102,090 2,306 104,396 160 10,788 100 83,876

Hydralazine 25mg Tab 0 0 0 0 0 0 0

Hydralazine 50mg Tab 0 0 0 0 0 0 0

Hydrochlorothiazide 25mg Tab 65,454 16,850 82,304 0 16,841 0 14,287

Hydrochlorothiazide 50mg Tab 1,234,956 381,152 1,616,108 3,000 384,877 4,500 1,528,931

Isoniazid 100mg Tab (INH) 80,204 14,807 95,011 1,620 8,541 0 67,820

Isoniazid 300mg Tab (INH) 0 0 0 0 0 0 0

Ketamin 50mg/ml 10ml Vial 17,672 2,913 20,585 50 5,044 188 17,536

Lidocaine 1% 20ml Vial 160 0 160 0 50 0 115

Lidocaine 1% 50ml Vial 1,070 362 1,432 0 354 0 20

Lidocaine 1% in 2ml Amp 17,887 0 17,887 0 4,168 59 13,867

Lidocaine 2% in 20ml Vial 17,339 7,474 24,813 251 7,788 494 19,044

Lidocaine 2% in 50ml Vial 3,367 800 4,167 0 302 0 3,475

Lidocaine 20mg/ml 5ml Amp 0 0 0 0 0 0 0

46

Page 52: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Lidocaine 5% 2ml Amp 3,308 2,100 5,408 0 2,120 30 3,471

Magnesium Sulfate 500mg/ml (50%) 10ml Amp 49,713 3,764 53,477 0 10,750 37 55,564

Magnesium Sulfate 500mg/ml (50%) 20ml Amp 5,733 630 6,363 0 419 1,360 3,988

Mebendazole 100mg Tab 4,226,602 2,002,542 6,229,144 9,790 2,361,043 8,931 4,856,764

Mebendazole 500mg Tab 15,000 0 15,000 0 0 0 0

Medroxyprogesterone acetate Depot 150mg/ml, in 1ml vial

678,771 100,007 778,778 9,194 160,940 5,153 601,890

Methyldopa 250mg Tab 2,016,115 1,374,040 3,390,155 0 1,211,225 24,836 2,553,721

Methylergometrine 0.125mg Tab 169,982 59,100 229,082 0 33,432 0 108,226

Methylergometrine 0.2mg/ml, 1ml Amp 14,965 2,640 17,605 1,200 6,423 0 4,380

Metoprolol 1mg/ml, in 5ml Amp 0 0 0 0 0 0 0

Metronidazole 120mg/5ml, in 100ml bottle, Susp 27,971 55,100 83,071 0 22,138 0 62,733

Metronidazole 200mg Tab 8,810,898 5,768,650 14,579,548 24,800 6,059,796 639,815 10,022,196

Metronidazole 200mg/5ml, in 100ml bottle, Susp 286,921 160,848 447,769 0 173,495 5 336,258

Metronidazole 200mg/5ml, in 60ml bottle, Susp 13,477 0 13,477 0 3,775 4,216 5,541

Metronidazole 250mg Tab 1,051,700 72,000 1,123,700 0 0 0 62,000

Metronidazole 400mg Tab 5,993,984 2,844,400 8,838,384 24,800 2,569,748 577,110 6,703,013

Metronidazole 500mg Tab 0 0 0 0 0 0 0

Metronidazole 5mg/ml, in 100ml bottle, infusion Sol 280,965 21,631 302,596 0 209,080 391 526,219

Morphine (sulfate,hydrochloride) 10mg/ml, in 1ml Amp

6,737 1,359 8,096 377 2,328 80 5,738

Naloxone 400mcg/ml (0.4mg/ml) in 1ml Amp 14,554 1,860 16,414 60 3,438 392 13,217

Nifedipine 10mg Tab/Cap 653,029 132,160 785,189 20,570 216,774 3,215 598,408

Nifedipine 20mg Tab/Cap 44,536 3,480 48,016 0 20,534 0 7,850

Norgestrel 0.03mg Cycle 171,320 66,155 237,475 0 103,099 1,106 176,793

47

Page 53: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Norgestrel 0.075mg Cycle 73,161 9,360 82,521 0 5,252 3,900 50,720

Oral rehydration salts (ORS , Resomal and low osmolar) 20.5g/Lit

1,662,427 1,589,395 3,251,822 0 1,181,593 306,440 1,738,941

Oral rehydration salts (ORS , Resomal and low osmolar) 27.9g/Lit

1,380,486 772,745 2,153,231 0 949,770 3,861 1,565,735

Oxytocine 10IU/ml in 1ml Amp 382,594 193,728 576,322 0 170,085 10,720 453,832

Paracetamol (Acetaminophen) 225mg/3ml, Amp (75mg/ml)

0 0 0 0 0 0 0

Paracetamol 100mg Tab 10,389,205 6,589,500 16,978,705 15,000 7,850,113 233,270 11,916,812

Paracetamol 100mg/ml, 15ml Drop 626 88 714 0 330 0 384

Paracetamol 120mg/5ml, 60ml Syr 431,561 200,820 632,381 4,900 277,091 12,114 391,480

Paracetamol 325mg Tab 19,170 11,900 31,070 0 22,840 0 8,230

Paracetamol 500mg Tab 27,913,668 18,047,350 45,961,018 15,000 20,603,556 3,192,364 27,684,310

Penicillin Benzyl (Peni G crystal) 1MU Vial 0 0 0 0 0 0 0

Penicillin Benzyl (Peni G crystal) 5MU Vial 36,743 1,122 37,865 0 8,087 0 26,399

Pethidine 100mg/ml, 1ml Amp 0 0 0 0 0 0 0

Pethidine 50mg/ml, 2ml Amp 0 0 0 0 0 0 0

Phenobarbital 100mg/ml, in 2ml Amp 742 560 1,302 0 223 0 1,004

Phenobarbital 200mg/ml, 1ml Amp 844 0 844 0 685 0 1,029

Phenobarbital 50mg/ml 5ml Amp 834 0 834 0 245 0 0

Povidone-Iodine 10% Topical Sol 22,640 8,017 30,657 25 10,189 157 21,277

Propranolol 10mg Tab 3,620 1,950 5,570 0 1,580 0 3,990

Propranolol 20mg Tab 0 0 0 0 0 0 0

Propranolol 40mg Tab 102,841 3,782 106,623 0 28,481 0 39,655

Quinine dihydrochloride 300mg/ml, in 2ml Amp 20,626 1,309 21,935 0 1,962 207 18,208

Ranitidine 25mg/ml, in 2ml Amp 10,456 3,166 13,622 0 4,350 0 19,626

48

Page 54: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Retinol (Vit A) 100,000 IU Amp 6,727 8,900 15,627 0 3,488 0 12,139

Retinol (Vit A) 100,000 IU Tab 724,345 399,700 1,124,045 3,000 116,864 33,820 790,885

Retinol (Vit A) 200,000 IU Cap 2,436,004 892,512 3,328,516 0 1,270,330 74,247 1,786,739

Retinol (Vit A) 25,000IU Cap 0 0 0 0 0 0 0

Retinol (Vit A) 50,000IU Cap 687,809 79,090 766,899 0 23,782 0 892,630

Rifampicin 150mg+Isoniazid 75mg (RH) Tab 310,516 95,365 405,881 0 149,693 0 135,566

Rifampicin 150mg+Isoniazid 75mg+Ethambutol 275mg (RHE) Tab

60,005 6,618 66,623 56 19,428 0 42,525

Rifampicin 150mg+Isoniazid 75mg+Pyrazinamide 400mg+Ethambutol 275mg (RHZE) per Tab

188,342 94,216 282,558 6,799 94,783 0 127,791

Rifampicin 300mg Tab 4,553 0 4,553 0 496 0 4,217

Rifampicin 60mg+Isoniazid 30mg (RH) Tab 37,207 9,708 46,915 1,336 12,551 0 22,048

Rifampicin 60mg+Isoniazid 30mg+Pyrazinamide 150mg (RHZ) Tab

21,303 7,864 29,167 1,076 5,652 0 17,534

Ringer lactate 1000ml IV infusion 228,796 131,681 360,477 0 132,770 2 254,153

Ringer lactate 500ml IV infusion 87,563 16,660 104,223 0 32,412 7,993 85,297

Salbutamol 0.05mg/ml (50mcg/ml) in 5ml Amp 20,233 4,247 24,480 300 10,510 182 20,787

Salbutamol 0.5mg/ml, in 1ml Amp 4,985 1,980 6,965 0 824 1,337 4,491

Sodium Chloride 0.9% 1000ml IV infusion (Normal Saline)

100,451 65,243 165,694 0 65,356 0 119,896

Sodium Chloride 0.9% 500ml IV infusion (Normal Saline)

28,072 4,960 33,032 0 8,729 1,911 20,461

Spironolactone 100mg Tab 0 0 0 0 0 0 0

Sulfamethoxazole 100mg+Trimethoprim 20mg Tab (Co-trimoxazole)

17,023,775 6,083,400 23,107,175 538,430 7,441,701 196,856 16,407,884

Sulfamethoxazole 200mg+Trimethoprim 40mg/5ml 50ml Susp (Co-trimoxazole)

347,628 42,189 389,817 910 124,876 9,872 259,484

Sulfamethoxazole 400mg+Trimethoprim 80mg 50ml Susp (Co-trimoxazole)

1,006,078 2,268,000 3,274,078 0 106,311 0 1,173,841

49

Page 55: CONTENTSgdpa.gov.af/Content/Media/Documents/PLISPre-definedReportQTR3... · Supply Chain Development . SPS . Strengthening Pharmaceutical Systems . USAID . US Agency for International

Medicines Beginning Stock Added Stock Grand Total Available

Donated Out Consumed quantity Reported Wastage Reported Ending Stock

Sulfamethoxazole 400mg+Trimethoprim 80mg Tab (Co-trimoxazole)

22,048,797 10,145,200 32,193,997 24,000 15,309,583 342,217 23,796,917

Zinc Sulfate 10mg Tab 0 0 0 0 0 0 0

Zinc Sulfate 20mg Tab 4,635,085 2,374,491 7,009,576 84,500 2,245,162 58,782 4,566,714

50


Recommended